Floatz logo

Auto3

Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Autolus LimitedCell therapyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

108 Active assets in the Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) cohort.

Asset / SponsorPhaseRating
Selinexor
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 3BB
DEXAMETHASONE
City of Hope Medical Center
Phase 2/3BB
Ifosfamide
University of California, Davis
Phase 3BB
Cyclophosphamide
Nathan Denlinger
Phase 3BB
Axicabtagene Ciloleucel
Zhujiang Hospital
Phase 3BB

View all 50 →

Same molecule, other indications

Auto3 is also rated in:

childhood acute lymphoblastic leukemiaDormant
CCC
Indicative ·
50 / 100
View asset →
B-cell acute lymphoblastic leukemiaDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →